Key Points

• Trimurthi has closed its trading window
• A board meeting is scheduled to discuss fund-raising proposals
• The closure affects designated persons and their immediate relatives

Details

Trimurthi (ISIN: INE314I01036) has announced the closure of its trading window in compliance with regulatory requirements. This action precedes an upcoming board meeting where fund-raising proposals will be discussed.

Trading Window Closure

The trading window closure applies to all designated persons of the company and their immediate relatives. This measure is in line with the Securities and Exchange Board of India (SEBI) regulations, specifically the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Upcoming Board Meeting

The board of directors is set to convene to consider and evaluate various fund-raising proposals. The exact date of the meeting has not been disclosed in the available information.

Implications

The closure of the trading window is a standard practice to prevent insider trading and ensure fair market practices. It suggests that the company is preparing for significant financial decisions that could potentially impact its stock price.

Investor Considerations

Investors and market participants should note that:

1. No trading activity by insiders will be permitted during this period
2. The outcome of the board meeting could have a material impact on the company's financial structure
3. Any decisions regarding fund-raising will be communicated to the public following the board meeting

Stakeholders are advised to await official announcements from Trimurthi for further details on the fund-raising proposals and their potential impact on the company's future operations and financial position.

Trimurthi , a manufacturer and trader of active pharmaceutical ingredients, has announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The company's Board of Directors approved these results at a meeting held on November 13, 2025.

Financial Highlights

• Revenue: The company reported a total income of Rs 3,639.14 crore for Q2 FY2026, compared to Rs 387.37 crore in the corresponding quarter of the previous year, marking a significant year-on-year growth.
• Net Profit: Trimurthi posted a net profit of Rs 52.47 crore for the quarter, showcasing a substantial increase from Rs 12.95 crore in Q2 FY2025.
• Half-Year Performance: For the half-year ended September 30, 2025, the company's total income stood at Rs 5,874.26 crore, with a net profit of Rs 64.03 crore.

Key Financial Metrics

Business Segment Performance

Trimurthi operates primarily in the pharmaceutical segment, focusing on the manufacture and trade of active pharmaceutical ingredients (bulk drugs). The company's financial results reflect its performance in this single business segment.

Balance Sheet Highlights

As of September 30, 2025, Trimurthi reported:

• Total Assets: Rs 7,180.33 crore
• Total Equity: Rs 2,560.96 crore
• Current Assets: Rs 7,061.96 crore, including inventories of Rs 305.64 crore

Corporate Governance Update

The company announced the resignation of Ms. Monam Kapoor from her position as an Independent Non-Executive Director, effective November 13, 2025. Ms. Kapoor cited pre-occupation and other personal commitments as reasons for her departure.

Trimurthi continues to adapt to market dynamics and regulatory requirements, as evidenced by its compliance with SEBI regulations and the timely filing of its quarterly results.

Investors and stakeholders are encouraged to review the detailed financial statements available on the company's website for a comprehensive understanding of Trimurthi's financial position and performance.